[Biphosphonates. Contribution to the treatment of malignant osteolysis].
Prier
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D004002:Clodronic Acid / Q000378:metabolism / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D010014:Osteolysis / Q000188:drug therapy* / Q000209:etiology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology
D000970:Antineoplastic Agents; D004002:Clodronic Acid; D012968:Etidronic Acid
Bisphosphonates. Contribution au traitement des ostéolyses malignes.